Review

J Innate Immun 2013;5:197–208
DOI: 10.1159/000346374

Received: November 2, 2012
Accepted after revision: December 6, 2012
Published online: February 5, 2013

Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections

Marine L.B. Hillairea Henk P. Haagsmanc Albert D.M.E. Osterhausa, b Guus F. Rimmelzwaana, b Martin van Eijkc

a Erasmus Medical Centre, Department of Viroscience, and b Viroclinics Biosciences BV, Rotterdam, and c Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

Key Words
Influenza A virus · Collectins · Innate immunity · Viral glycosylation · Pulmonary defense · Antiviral drugs · C-type lectins · Sialic acids · Lung inflammation

Abstract
Influenza A viruses (IAV) cause respiratory tract infections annually associated with excess mortality and morbidity. Non-specific, innate immune mechanisms play a key role in protection against viral invasion at early stages of infection. A soluble protein present in mucosal secretions of the lung, surfactant protein D (SP-D), is an important component of this initial barrier that helps to prevent and limit IAV infections of the respiratory epithelium. This collagenous C-type lectin binds IAVs and thereby inhibits attachment and entry of the virus but also contributes to enhanced clearance of SP-D-opsonized virus via interactions with phagocytic cells. In addition, SP-D modulates the inflammatory response and helps to maintain a balance between effective neutralization/killing of IAV, and protection against alveolar damage resulting from IAV-induced excessive inflammatory responses. The mechanisms of interaction between SP-D and IAV not only depend on the structure and binding properties of SP-D but also on strain-specific features of IAV, and both issues will be discussed. SP-D from pigs exhibits distinct anti-IAV properties and is discussed in more detail. Finally, the potential of SP-D as a prophylactic and/or therapeutic antiviral agent to protect humans against infections by IAV is discussed.

Introduction

Collectins, First-Line Defense Proteins of the Innate Immune System

The innate immune system plays an essential role in host defense since it is the initial barrier that provides protection against invading pathogens. It includes physical barriers such as the skin, the mucosal epithelia of the lungs and the gastrointestinal and reproductive tract, different cells such as macrophages, neutrophils or natural killer cells and soluble molecules such as the components of the complement system, pattern recognition receptors and cytokines. Upon microbial challenge, the innate immune system generates an acute-phase-like response, characterized by limited specificity and lack of memory,
in contrast to the adaptive immune response. The recognition of nonself antigen is key in the induction of the innate immune response. Such nonself antigens include pathogen-associated molecular patterns known as PAMPs, which are conserved molecular signatures of pathogens such as lipopolysaccharide, double- or single-stranded RNA, mannose-rich glycans or peptidoglycans. PAMPs are highly conserved molecular structures that play a key role in the survival and/or virulence of pathogens [1]. Several cells and molecules of the innate immune system can recognize PAMPs, including a group of innate immune proteins known as ‘collectins’ which are involved in early stages of host defense against a broad range of microorganisms that include Gram-positive and Gram-negative bacteria, viruses, fungi and yeasts.

The collectin family includes different members and although they are considered evolutionary ancient, their occurrence and structural/functional characteristics show (subtle) variations even amongst mammalian species. In humans, the three major members of this protein family comprise surfactant protein A (SP-A), surfactant protein D (SP-D) and mannose-binding lectin. SP-A and SP-D are constitutively secreted into the lungs by alveolar type II cells and unciliated bronchial epithelial cells [2], but they can also be produced in other mucosal tissues [3–5]. In contrast, mannose-binding lectin is a serum collectin that is produced in the liver and plays an important role in complement activation via the lectin pathway. The polypeptide structure of all collectins is characterized by the presence of a cysteine-rich N-terminal domain, a collagenous domain, a trimerizing neck domain and a C-type lectin domain (carbohydrate recognition domain, CRD) which adopts a stable carbohydrate-binding conformation in the presence of Ca²⁺ (fig. 1a). All collectins known to date assemble into trimers and in most cases these subunits arrange into higher-order oligomers (fig. 1b) that are able to recognize and bind to patterns of glycoconjugates expressed on the surface of pathogens. As a result of this interaction, collectins participate in neutralization and clearance of a wide range of microorganisms including bacteria, fungi and viruses [6]. This review focuses on the role of the ‘pulmonary collectin’ SP-D in early defense against the respiratory pathogen influenza A virus (IAV). The following paragraph summarizes several important characteristics of IAV.

**Characteristics of IAV**

IAV is a major cause of respiratory tract infections resulting in a highly contagious disease that leads to excess morbidity and mortality every year [7]. Different sub-
types of IAV are defined depending on their two surface proteins, the hemagglutinin (HA) and the neuraminidase (NA). A total of 17 types of HA and 9 types of NA are reported and in theory any combination is possible. HA is the predominant protein in the viral envelope and plays an important role in the virus cycle since it is the IAV receptor binding protein that recognizes sialic acid (SA). This receptor-mediated interaction results in attachment, entry and fusion of the viral envelope with the endosomal membrane. By distinguishing between

Fig. 2. Structure of the IAV surface protein HA. a Ribbon diagram of the HA monomer, consisting of the HA1 subunit (globular domain, black ribbon) and the HA2 stalk region (grey ribbon) which contains the fusion peptide (sticks, FP). Location of the SA receptor is indicated by a bound α(2,6)-linked SA moiety (spheres) attached to Galβ1–4GlcNac (sticks). b Molecular organization of a mature HA trimer. Three HA monomers with HA1 and HA2 domains and SA receptors visualized as in a assembled into a single mature HA molecule as present in the viral envelope. c Detailed view of a single globular domain (HA1) derived from the 2009 pandemic H1 structure. Spheres indicate the locations of potential N-glycosylation sites as generally found in H1 subtype strains of IAV. Shown are the predicted glycosylation patterns with numbers indicating the asparagine residues within the HA protein sequence that correspond with these glycosylation sites. These are shown for A/NL/26/07 (representing a recent seasonal H1 strain: No. 54, 125 and 160) and for A/NL/602/09 (representing the pandemic 2009 H1N1 strain) either only present in the pandemic 2009 H1N1 strain (No. 276, highlighted with an asterisk) or shared with seasonal H1 (all others). The SA receptor is shown as described in a and indicated with R. In all panels top view is given at the top and side view at the bottom (adapted from the H1 structure of A/California/04/2009, PDB accession No. 3UBE).
specific SA linkages, the receptor specificity dictates viral tropism and host specificity. The HA of human IAVs recognizes α(2,6)-linked sialosaccharides (NeuAcα2–6Gal) that are mainly present in the upper respiratory tract of humans [11–13], whereas the HA of avian IAV recognizes α(2,3)-linked sialosaccharides (NeuAcα2–3Gal) that are found in the avian gastrointestinal tract and in the lower region of the human respiratory tract [14–16]. After the fusion event, the RNA segments are released in the cytosol and delivered into the nucleus where replication and transcription of the viral RNA take place. New viral particles are assembled at the membrane and budding is facilitated by the viral NA that enzymatically cleaves off SA residues from the infected cell, resulting in release of the virus from the infected host cells.

Most commonly inactivated influenza vaccines are used to protect individuals from contracting influenza and these vaccines mainly aim at the induction of antibodies against IAV membrane glycoproteins in particular HA. However, due to their high mutation rate, IAV evolve rapidly and undergo antigenic changes that are known as antigenic drift [17]. As a consequence, vaccines have to be adapted annually to match the circulating seasonal IAV. Moreover, novel antigenically distinct IAV can be introduced into the human population (antigenic shift), which may give rise to pandemic outbreaks and numerous deaths before a sufficient number of vaccine doses can be produced and distributed, as was the case during the 2009 pandemic [18]. Considering these limitations, it is important to develop alternative antiviral strategies that may help to protect the human population against infections with novel IAV. SP-D, a natural component of our innate immune system, is able to recognize and neutralize a wide range of subtypes of IAV and could be a venue for development of a novel, broad-spectrum antiviral drug against IAV.

**SP-D-Mediated Inhibition of IAV in vitro**

*Multivalency of Interactions between SP-D and IAV*

SP-D polypeptides assemble into trimers and these trimeric subunits can be further oligomerized into higher-order multimers like dodecamers, stabilized by disulfide bonds present in the N-terminal region (fig. 1b) [19]. The trimeric configuration of each subunit facilitates multivalent high-avidity interactions between three clustered CRDs at the C-terminus of a single collectin arm, with specific patterns of glycoconjugates as present on the surface of IAV. The dimensions and spatial organization of three clustered SP-Ds match those of the trimeric HAs on IAV (fig. 2b) and this results in strong binding of viral glycans as present on the HA of IAV. Although there are reports indicating that SP-D also binds glycans present on NA [20], this interaction is considered less important given the 5-fold higher abundance of HA on the viral surface and the more extended configuration of the HA molecule. Of note, several studies showed that SP-D is able to inhibit NA activity either indirectly by binding adjacent HA molecules causing steric hindrance and blocking access of NA substrates (studies with intact virus [21]), or directly by binding NA resulting in reduction of NA activity [22].

Aggregation of IAV is an important neutralization mechanism that helps to prevent viral particles from infecting pulmonary epithelial cells. In addition, viral aggregate formation allows phagocytic cells to enhance neutralization and clearance of IAV more efficiently [23]. Viral aggregation requires multitrimeric structures like dodecameric SP-D. Several IAV neutralization studies with SP-D preparations expressed and purified in different degrees of assembly have underlined this correlation between the state of oligomerization and the IAV neutralization activity [24–26]. These results are of special interest since in humans there is a common polymorphism at position 11 (Met/Thr) of the mature protein sequence and the SP-D Thr/Thr11 form assembles predominantly as trimers that also have reduced antiviral capacity. Therefore, the presence of this polymorphism in humans may correlate with an enhanced susceptibility to IAV infections [24].

**SP-D Binds IAV via Its CRD**

The first in vitro studies showing that SP-D inhibits IAV were performed by Hartshorn et al. [27]. By using native rat SP-D and recombinant forms of rat and human SP-D they could demonstrate SP-D-mediated inhibition of H3N2 and H1N1 subtypes of IAV. This inhibitory activity proved to be Ca$^{2+}$-dependent, indicating that the CRD of SP-D is involved in interactions with glycans present on the surface of IAV (fig. 3a). Several in vitro studies were published illustrating the comparatively strong inhibitory activity of SP-D against IAV and of the human collectins, SP-D is in general the most potent in neutralizing IAV as compared to SP-A and mannos-binding lectin [27–29].

Recognition of IAV by SP-D is mediated via its CRD. Like all collectins (except CL-P1), SP-D is a mannosetype lectin, preferentially binding mannos-type glycans over galactose-type glycans [30]. However, the carbohy-
drate binding specificity of SP-D shows subtle animal species-specific variations and this is determined by differences in specific residues located in the sugar binding pocket of the CRD [31, 32]. While human SP-D (hSP-D) has a high affinity for N-acetyl-mannosamine, rat and mouse SP-D preferentially recognize myo-inositol, maltose and glucose [31] and porcine SP-D (pSP-D) prefers mannose, maltose and glucose [33, 34]. Apart from the glycan species, the number of glycans present on HA (and to a lesser extent on NA) and their exact location on the IAV surface proteins are also important factors in mediating recognition by SP-D. Several investigations have indicated that the number of Asn-linked glycosylations on HA affects the susceptibility of IAV to inhibition by SP-D and that the degree of HA glycosylation correlates with virulence of IAV in mice. This will be described in more detail in the section below.
HA Glycosylation versus Neutralization of IAV by SP-D

Glycosylation of IAV is not only important for structural stability and integrity of HA and NA, but it also provides an effective means of immune evasion by shielding antigenic sites on the viral HA [35]. As a result of antigenic drift, human strains tend to accumulate glycosylation sites and in vivo experiments showed that mice are less susceptible to infection with more recent human IAV strains [36]. The accumulation of glycans on HA might be driven by antibody pressure since glycosylation may result in masking of neutralization epitopes present on HA and subsequent evasion from antibody-mediated neutralization by the host [37]. This inverse correlation between the extent of glycosylation of a particular IAV strain and its virulence in naïve mice precludes involvement of preexisting adaptive immunity and was attributed to increased IAV susceptibility to SP-D-mediated inhibition, as well as recognition and killing of virus that involves the mannose receptor on macrophages [36, 38–41]. Of interest, the HA proteins of pandemic viruses (1918, 1957, 1968 and 2009) are poorly glycosylated and these caused alveolitis and bronchiolitis, in contrast to a seasonal H1N1 strain that induced only mild disease in infected mice [42]. The low number of N-linked glycans on these viruses correlates with a low susceptibility to SP-D-mediated neutralization [42, 43]. In contrast, seasonal viruses that are sensitive to SP-D cause relatively mild disease [42]. It can be hypothesized that infection with a SP-D-insensitive IAV strain results in higher virus replication and more clinical signs while infection with a SP-D-sensitive strain leads to a milder clinical course as SP-D can neutralize the virus and may help to reduce the spread of virus (fig. 4). However more studies are needed to determine the correlation between sensitivity to SP-D, glycosylation and pathogenicity of IAV.

In recent studies, reverse genetics on IAV was applied to study the impact of introducing or deleting N-glycosylation sites in the viral HA for IAV susceptibility to SP-D-mediated neutralization. The number of glycosylation sites that was introduced in the HA of IAV A/Hong Kong/1/68 (H3N2) determined the sensitivity of the virus to hSP-D [44] and was shown to be inversely correlated with viral virulence. These findings were confirmed using another H3N2 virus showing that presence of N-linked glycans at positions N165 and N246 contributed to attenuation of the virus and increased susceptibility to SP-D [40] and that the loss of a single glycosylation site at N246 was associated with resistance to SP-D but also to higher virulence in mice [39]. Previously it was also shown in studies with the reassortant H3N2 strain X79 that deletion of the glycosylation site at position N165 of the HA of IAV resulted in decreased sensitivity to SP-D inhibition [45]. Furthermore, it was shown that the N-linked glycosylation site at position N165 in H3N2 virus is absent in a collectin-resistant strain [46]. The importance of N165 as an important target for SP-D to interact with H3 subtypes is underlined by a study that described the predicted glycosylation profiles of various IAV HA subtypes. Analysis of 2,800 H3N2 full-length sequences (from all hosts and geographic regions) revealed that in general H3s have up to 6 glycosylation sites in their globular domain of which N165 appears to be the most conserved glycosylation site in H3 sequences [47]. This may at least in part explain why IAV strains of the H3 subtype are in general much more susceptible to SP-D-mediated neutralization as compared to IAV strains from other HA subtypes.

The correlation between glycan attachment sites on the HA and susceptibility to neutralization by SP-D was also demonstrated for several IAV strains of the H1N1 subtype. Based upon H1 sequence numbering of the mature protein, glycosylation of the head region of H1 tends to be clustered in 2 distinct regions: around the base of the head region (centered around N54 and N87) or in the globular head region (centered around 125 and 160 [47]; fig. 2c). Interestingly, the N-glycan at N87 has been present in all strains since 1977 and was shown to be important for inhibition by SP-D [46]. This glycan was predicted to be absent in the pandemic 1918 strain that also lacked glycosylation in the globular head region [48]. SP-D sensitivity tests using a panel of different H1N1 isolates revealed that glycans at N125 and N155 are important for inhibition by SP-D and this was underlined by virulence studies in mice [41]. By using PR-8 as a model strain for the introduction of N-glycosylation sites it was shown that especially N125 appears important for neutralization by SP-D [43], probably due to the location of N125 being in close proximity of the SA receptor. Recently, our group performed a reverse genetics study in which the pandemic 2009 H1N1 strain and a seasonal 2007 H1N1 strain were used to investigate the relative importance of the number and the position(s) of N-glycosylation sites in the head region of the HA for susceptibility of these IAV strains to the neutralizing activity of pSP-D [49]. It was shown that in contrast to the seasonal H1N1 strain, pandemic 2009 H1N1 lacks the 2 important N-linked glycans at N125 and N160 in its globular head region, making this strain highly resistant again pSP-D; by introducing these 2 N-glycans into the pandemic 2009
strain this resistance was counterbalanced. The reverse effect was observed using the seasonal H1N1 strain (susceptible to SP-D) and deleting the N125 glycan, resulting in a mutant that is much more resistant to SP-D. Interestingly, this same study showed that deletion of N276, present at the base of the head region of HA from pandemic H1N1 but absent in seasonal H1N1, substantially enhanced resistance against pSP-D. Taken together, these findings illustrate the importance of the degree of HA glycosylation and which positions/regions of the HA appear relatively important to facilitate glycan-dependent interactions between HA and SP-D resulting in more efficient clearance of IAV. IAV strains that circulate in low-mutation-pressure hosts like pigs and birds generally share poorly glycosylated globular domains of their HAs and when successfully introduced into the human population, may develop into pandemics (2009 H1N1, 1918 H1N1 [50]) or display pandemic potential as in the case of glycan-deficient H5N1 strains [51]. It remains to be investigated how resistance of these IAVs to early innate immune defense components, such as SP-D, contribute to their virulence and clinical severity that in most cases follows after infection with these strains. Figure 4 illustrates a hypothetical comparison between the degree of viral glycosylation, SP-D sensitivity, tissue tropism and relative virulence, restricted for those subtypes that are known to infect the human population.

**Immunomodulatory Roles of SP-D**

Binding of IAV by SP-D contributes to immediate protection against infection due to aggregation of viral particles, resulting in a reduction of the number of infectious particles in the lungs. However, the formation of SP-D/IAV complexes can also result in distinct interactions with immune cells leading to enhanced phagocytosis and modulation of the inflammatory response. Extensive studies on the interactions between neutrophils and SP-D have shown that SP-D is chemotactic for neutrophils [52, 53] and can bind SIRPa and SIRPβ [54], two surface proteins on neutrophils involved in neutrophil migration, phagocytosis and cytokine secretion. After IAV infection of the respiratory tract, neutrophils infiltrate the site of infection and are activated. IAV can cause neutrophil dysfunction and induce apoptosis, which may predispose to secondary bacterial infections. IAVs are also responsible for the deactivation of the neutrophils by

---

**Fig. 4.** Hypothetical correlation between the number of N-glycosylation sites, sensitivity to SP-D, and relative virulence. It is hypothesized that a higher degree of HA-glycosylation results in higher susceptibility to SP-D-mediated neutralization that leads to a reduced degree of virulence displayed by these IAV strains. A lower number of glycosylations correlates with higher virulence. These correlations are shown for seasonal IAVs [highlighted in green: H3N2 subtype (left panel) and H1N1 subtype (middle panel)] and for avian H5N1 (blue) and pandemic H1N1 (red) (right panel). Indicated are the number of N-glycosylation sites in the head region of HA, sensitivity to SP-D, and relative virulence (on a scale from 0 to 100). For longer circulating IAV subtypes (H3N2 and H1N1) evolution of these viral characteristics is displayed on the x-axis as a function of time (years) (color only in online version). HAU = HA units.
inhibiting the respiratory burst (rapid release of reactive oxygen species by phagocytic cells to degrade internalized pathogens). This phenomenon is mediated via HA which is able to cross-link sialylated surface receptors of the cell. Multimers of RhSP-D enhance binding of IAV to neutrophils in vitro. This is thought to be mediated via SP-D-induced aggregation of the virus, which would promote the binding of these large aggregates to neutrophils and would help the clearance by phagocytic mechanisms [27, 55]. Multimeric forms of SP-D also enhance neutrophil activation and protect the neutrophils against deactivation caused by IAV [55, 56] in contrast to trimeric forms of RhSP-D which inhibit IAV less efficiently, do not cause viral aggregation and are unable to protect neutrophils against deactivation [23]. Interactions of SP-D with neutrophils can be influenced by external factors. During acute infection, neutrophils and SP-D collaborate to clear IAV. However, if there is a chronic neutrophil activation preceding IAV infection, this will interfere with SP-D-mediated protection of neutrophils against IAV infection [57]. Furthermore, human neutrophil defensins interfere with the antiviral properties of SP-D [58].

SP-D can also interact with TLR2 and TLR4 [59, 60]. It is known that TLR4 mediates lung injury during H5N1 infection [61] and other studies showed that SP-D downregulates the inflammatory response mediated via TLR4 after lipopolysaccharide exposure in vitro [60]. Interestingly, it was demonstrated in ferrets and macaques infected with a lethal dose of H5N1 that the expression of SP-D mRNA is decreased [62]. A similar effect was observed in experiments with human alveolar type II cells which show a reduced secretion of SP-D after infection with H1N1 virus [63]. Therefore it can be hypothesized that due to the decrease of SP-D expression during H5N1 infection, TLR4 signaling is not downregulated and may contribute to acute lung injury during IAV infection.

Unique Properties of SP-D from Pigs

Several studies have shown that pSP-D can inhibit IAV of various subtypes more efficiently than hSP-D [22, 33] and that pSP-D can bind hSP-D-resistant strains that belong to the H5N1 subtype and pandemic 2009 H1N1 subtype although inefficiently [22, 43]. These species-specific differences in anti-IAV activity can be explained by the presence of unique structural properties in the CRD of pSP-D which are absent in SP-Ds from other animal species characterized to date [64]. Firstly, the CRD of pSP-D contains an N-linked, complex oligosaccharide at Asn303 that is fully sialylated with α(2,6)-linked SAs [65]. It was shown that the presence of terminal SAs on this complex glycan in the CRD contributes to the hemagglutination-inhibitory capacity of pSP-D against IAV [33, 66] (fig. 3b). This interaction appears even more relevant for pSP-D-mediated neutralization of IAVs that are poorly glycosylated [66]. Secondly, the CRD of pSP-D contains a unique tripeptide loop region that alters the lectin site conformation of the CRD, as described in a recent study on the crystal structure of a neck-CRD fragment of pSP-D [67]. Modeling studies suggest that this GSS-loop region facilitates interactions with distal portions of branched mannoside and results in distinct, high-affinity interactions between pSP-D and mannose-rich oligosaccharides expressed on the IAV surface.

Of interest, although pigs can be infected by IAV, the mortality rate is low (<1%) and they may be partially protected against infection by pSP-D [68]. The 2009 pandemic H1N1 viruses are of swine origin and are poorly glycosylated, making them fully resistant to neutralization by human SP-D [43] and less sensitive to inhibition by pSP-D [49]. This could favor escape from recognition by SP-D. Furthermore, commercial pigs have a limited life span which limits the selective pressure mediated by antibodies compared to humans [17, 69, 70]. It could be hypothesized that components of the innate immune system are more important for selective pressure than the adaptive immune system and antibodies in particular. Of interest, antigenic evolution is associated with a gain of N-linked glycosylation sites [71, 72] and therefore pandemic influenza viruses such as 2009 pandemic H1N1 may become more susceptible to the action of SP-D, which may contribute to restricted tropism to the upper respiratory tract, comparable to seasonal IAV of the H3N2 subtype and prepandemic H1N1 viruses [73].

Role of SP-D against IAV in vivo

SP-D knockout mice have been generated for more than 10 years ago. Mice heterozygous for the SP-D gene produce 50% less SP-D but display a normal phenotype. SP-D-deficient mice show a progressive accumulation of surfactant lipids and SP-A and SP-B in the alveolar space, the alveolar phospholipid pool being 8 times higher compared to the wild-type mice. There is also an accumulation of macrophages and alveolar type II cells are hyperplastic and contain giant lamellar bodies [74]. This sug-
gests that SP-D is important for surfactant homeostasis in the lungs. The phenotype of SP-D null mice can be reversed by administration of recombinant SP-D to their lungs. Of note, a mutant lacking the collagen domain of SP-D failed to reverse the phenotype [75], indicating that multimerization of SP-D is required to restore lung homeostasis.

After infection of wild-type mice with highly glycosylated IAV, endogenous SP-D increases while SP-D-deficient mice show a decreased viral clearance that can be reversed if RhSP-D is administered to the SP-D-deficient mice. However, during infection with a poorly glycosylated IAV that was resistant to inhibition by SP-D no difference was observed between wild-type and the SP-D knockout mice [76]. This result illustrates that SP-D-mediated clearance of IAV is affected by the degree of viral glycosylation of a particular strain.

Perspectives for SP-D as a Novel Antiviral Drug

To treat infected individuals, two classes of licensed antiviral drugs against influenza exist. The first are the adamantanes (amantadine and rimantadine), which inhibit the proton channel function of the matrix 2 (M2) protein. The other class of antiviral drugs comprises the NA inhibitors, zanamivir and oseltamivir. Unfortunately, the use of these antiviral drugs has some drawbacks such as side effects but also the emergence of resistant strains. For example, seasonal H3N2 IAV resistant to amantadine emerged in 2000 in Asia and has been the predominant strain ever since [77]. In addition, most of the seasonal H1N1 viruses isolated in the influenza season 2008–2009 were resistant to oseltamivir [77–79]. Clearly there is a need for novel classes of antiviral drugs that can be used to treat IAV infections and that do not suffer from these disadvantages.

The use of SP-D as an antiviral drug would offer several advantages. SP-D and especially pSP-D neutralize a broad range of IAVs and, in contrast to the use of NA inhibitors, it is unlikely that a single mutation in the genome of IAV would induce resistance against the antiviral activity of SP-D. Furthermore, SP-D can be administered into the airways to provide acute protection against invading IAV particles. Since SP-D is a naturally occurring substance in the airways, little toxic effects are anticipated and a relatively high immunogenic tolerance for such a biotherapeutic drug in humans. So far, only a few studies have addressed the role of SP-D as a potential antiviral drug. Mice that received a recombinant trimeric neck-CRD fragment of hSP-D before or repeated doses for several days after inoculation with respiratory syncytial virus displayed lower viral loads compared to untreated mice [80]. As for IAV, a recent study with a similarly truncated hSP-D molecule that also had two mutations engineered into its CRD (D325A/R343V) showed decreased morbidity and enhanced viral clearance in an infection model using mice in contrast to using oligomeric wild-type hSP-D [81]. These first successful anti-IAV studies in vivo can be considered as a major step forward in using SP-D as an antiviral drug against IAV. However, these studies involved coadministration of the modified SP-D after preincubation with IAV followed by application of the SP-D/IAV mixture to the animals. The potency of SP-D as an effective prophylactic or therapeutic drug requires further investigation.

Conclusions

SP-D shows strong antiviral properties against IAV in vitro and recent in vivo data have indicated that derivatives of this innate immune protein show potential to become a novel, antiviral drug. Of special interest, wild-type pSP-D exhibits strong antiviral properties against a much broader range of IAV strains/subtypes compared to hSP-D as it is naturally expressed in the airways. Future studies that are aimed to improve the antiviral activity of an hSP-D-based antiviral drug will benefit from our expanding knowledge on structure and properties of pSP-D.

Acknowledgement

This work was supported by grant 10388 from the Technology Foundation STW (Stichting Technische Wetenschappen).

References

4 Bourbon JR, Challely-Heu B: Surfactant pro-
teins in the digestive tract, mesentery, and
other organs: evolutionary significance.
Comp Biochem Physiol A Mol Integr Physiol

5 Herias MV, Hogenkamp A, van Asten AJ,
Tersteeg MH, van Eijk M, Haagsman HP. Ex-
pression sites of the collectin SP-D suggest its
importance in first line host defence: power of
combining in situ hybridisation, RT-PCR and
immunohistochemistry. Mol Immunol 2007;
44:3324–3332.

6 Hartshorn KL: Role of surfactant protein A
and D (SP-A and SP-D) in human antiviral
host defense. Front Biosci (Schol Ed) 2010;2:
527–546.

7 World Health Organization: Influenza (Se-
asonal); Fact Sheet No. 211. WHO, Geneva,
2009.

8 Wile DC, Skehel JJ: The structure and func-
tion of the hemagglutinin membrane glyco-

9 Wilson IA, Cox NJ: Structural basis of im-
une recognition of influenza virus hemag-
771.

10 Skehel JJ, Wile DC: Receptor binding and
membrane fusion in virus entry: the influenza
hemagglutinin. Annu Rev Biochem 2000;69:
531–569.

11 Rogers GN, D’Souza BL: Receptor binding
properties of human and animal H1 influenza

12 Thompson CI, Barclay WS, Zambon MC,
Hartshorn KL, White MR, Tecle T, Sorensen
G, Holmskov U, Crouch EC: Viral aggregat-
ing of anti-influenza activity of surfactant pro-

13 van Riel D, Munster VJ, de Wit E, Rimmel-
zaan GF: Assess-
ment of the antiviral properties of recombi-
nant porcine SP-D against various influenza

14 Brown-Augsburger P, Hartshorn KL, Chang
D, Rust K, Fliszar C, Welsus HG, Crouch EC:
Site-directed mutagenesis of Cys-15 and Cys-
20 of pulmonary surfactant protein D. Ex-
pression of a trimeric protein with altered anti-
 viral properties. J Biol Chem 1996;271:
13724–13730.

15 Hartshorn KL, White MR, Tecle T, Tornoe I,
Crouch EC, Smith K, McDonald B, Ear-
der PH, Head J: Recognition of mannosyl-
ated ligands and influenza A virus by human
surfactant protein D: contributions of an ex-
tended site and residue 343. Biochemistry

16 van Eijk M, White MR, Crouch EC, Baten-
burg JJ, Vaandrager AB, van Golde LMG,
Haagsman HP, Hartshorn KL: Pulmonary
surfactant collects show distinct interactions
with influenza A viruses; role of the N-linked
oligosaccharides in the carbohydrate recog-
1440.

17 Soerenson CM, Nielsen OL, Willis A,
Heegaard PM, Holmskov U: Purification,
characterization and immunolocalization of the
N-glycosylation of the hemagglutinin of influenza
8492.

18 Girard MP, Tam JS, Assoussou OM, Kiency MP,
The 2009 A (H1N1) influenza virus pandemic: a

19 Crouch EC, Persson A, Chang D, Heuser J:
Molecular structure of pulmonary surfactant
protein D (SP-D). J Biol Chem 1994;269:
17311–17319.

20 Hartshorn KL, White MR, Voelker DR, Co-
burn J, Zaner K, Crouch EC: Mechanism of
binding of surfactant protein D to influenza A
viruses: importance of binding to haemagglu-
tinin to antiviral activity. Biochem J 2000;351:
449–458.

21 Tecle T, White MR, Crouch EC, Hartshorn
KL: Inhibition of influenza viral neuraminid-
ase activity by collectins. Arch Virol 2007;
152:1731–1742.

22 Hillaire ML, van Eijk M, van Trierum SE, van
Riel D, Saelens X, Romijn RA, Hemrika W,
Fouchier RA, Kuiken T, Osterhaus AD,
Haagsman HP, Rimmelzaan GF: Assess-
ment of the antiviral properties of recombi-
nant porcine SP-D against various influenza
139.

23 Brown-Augsburger P, Hartshorn KL, Chang
D, Rust K, Fliszar C, Welsus HG, Crouch EC:
Site-directed mutagenesis of Cys-15 and Cys-
20 of pulmonary surfactant protein D. Ex-
pression of a trimeric protein with altered anti-
 viral properties. J Biol Chem 1996;271:
13724–13730.

24 Hartshorn KL, White MR, Tecle T, Tornoe I,
Sorensen GL, Crouch EC, Holmskov U: Re-
duced influenza viral neutralizing activity of
natural human trimers of surfactant protein D.

25 Tecle T, White MR, Sorensen G, Gantz D, Ka-
cak N, Holmskov U, Smith K, Crouch EC,
Hartshorn KL: Critical role for cross-linking of
trimeric lectin domains of surfactant pro-
tein D in antiviral activity against influenza A

26 Hartshorn KL, White MR, Tecle T, Sorensen
G, Holmskov U, Crouch EC: Viral aggregat-
ging and osonizing activity in collectin tri-
mers. Am J Physiol Lung Cell Mol Physiol
2010;298:L79–L88.

27 Hartshorn KL, Crouch EC, White MR, Eggle-
ton P, Tauber AI, Chang D, Sastry K: Evi-
dence for a protective role of pulmonary sur-
factant protein D (SP-D) against influenza A

28 Hartshorn KL, White MR, Shepherd V, Reid
KBM, Jansenius JC, Crouch EC: Mechanisms of
anti-influenza activity of surfactant pro-
tein A and D: comparison with serum col-

29 White MR, Crouch E, Chang D, Hartshorn
KL: Increased antiviral and osonic activity of
a highly multimerised collectin chimera. Bio-
chem Biophys Res Commun 2001;286:206–
213.

30 Rust K, Grosso L, Zhang V, Chang D, Persson
A, Longmore WJ, Cai GZ, Crouch EC: Hu-
man surfactant protein D; SP-D contains a C-
type lectin carbohydrate recognition domain.

31 Crouch EC, Smith K, McDonald B, Briner D,
Linders B, McDonald J, Holmskov U, Head J,
Hartshorn KL: Species differences in the carbo-
hydrate binding preferences of surfactant
protein D. Am J Respir Cell Mol Biol 2006;35:
84–94.

32 Crouch E, Hartshorn K, Horlacher T, Mc-
Donald B, Smith K, Cafarella T, Seaton B, See-
berger PH, Head J: Recognition of mannosyl-
ated ligands and influenza A virus by human
surfactant protein D: contributions of an ex-
tended site and residue 343. Biochemistry

33 van Eijk M, White MR, Crouch EC, Baten-
burg JJ, Vaandrager AB, van Golde LMG,
Haagsman HP, Hartshorn KL: Pulmonary
surfactant collects show distinct interactions
with influenza A viruses; role of the N-linked
oligosaccharides in the carbohydrate recog-
1440.

34 Reading PC, Morey LS, Crouch EC, Anders
EM: Collectin-mediated antiviral host def-
ense of the lung: evidence from influenza vi-
8212.

35 Das SR, Hensley SE, David A, Schmidt L,
Gibbs JS, Pugho P, Ince WL, Bennink JR,
Yewdell JW: Fitness costs limit influenza A
virus hemagglutinin glycosylation as an im-
mune evasion strategy. Proc Natl Acad Sci

36 Reading PC, Miller JL, Anders EM: Involvement of
the mannose receptor in infection of macrophages
74:5190–5197.

37 Reading PC, Pickett DL, Tate MD, Whitney
PG, Job ER, Brooks AG: Loss of a single N-
linked glycan from the hemagglutinin of
influenza virus is associated with resistance to
collectins and increased virulence in mice. Respi-
R Respir 2009;10:117.

38 Tate MD, Job ER, Brooks AG, Reading PC:
Glycosylation of the hemagglutinin modu-
lates the sensitivity of H3N2 influenza virus-
es to innate proteins in airway secretions and
virulence in mice. Virology 2011;413:
84–92.

39 Tate MD, Brooks AG, Reading PC: Specific
sites of N-linked glycosylation on the hemag-
glutinin of H1N1 subtype influenza A virus
determine sensitivity to inhibitors of the in-
nate immune system and virulence in mice. J

Hillaire/Haagsman/Osterhaus/
Rimmelzaawan/van Eijk
IAV–Neutralization by SP-D


